ACAD
$28.24
$-0.14 (-0.49%)-0.49%
ClosedLoading chart...
IndexN/A
Market Cap4.84B
Enterprise Value4.40B
Income$0.02B
Sales$0.24B
EmployeesN/A
P/E13.71
P/S4.22
P/B3.69
P/C43.02
EV/EBITDA29.19
EV/SalesN/A
EPS (ttm)2.06
EarningsN/A
Gross Margin91.69%
Oper. Margin9.78%
Profit Margin36.49%
Volume1.03M
Shs Outstand0.17B
Change-0.49%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $957.80M | $726.44M | $517.24M | $484.14M | $441.75M | $339.08M | $223.81M | $124.90M |
| Cost of Revenue | $81.84M | $45.73M | $10.17M | $19.14M | $20.55M | $19.60M | $18.33M | $13.06M |
| Gross Profit | $875.96M | $680.71M | $507.07M | $465.00M | $421.20M | $319.48M | $205.48M | $111.84M |
| Gross Margin | 91.46% | 93.70% | 98.03% | 96.05% | 95.35% | 94.22% | 91.81% | 89.54% |
| Operating Expenses | $645.16M | $754.09M | $730.66M | $635.44M | $707.79M | $566.02M | $452.92M | $404.25M |
| Operating Income | $230.79M | $-73.38M | $-223.60M | $-170.44M | $-286.59M | $-246.54M | $-247.44M | $-292.41M |
| Operating Margin | 24.10% | -10.10% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% |
| Net Income | $226.45M | $-61.29M | $-215.97M | $-167.87M | $-281.58M | $-235.26M | $-245.19M | $-289.40M |
| Net Margin | 23.64% | -8.44% | -41.76% | -34.67% | -63.74% | -69.38% | -109.56% | -231.71% |
| EPS (Basic) | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | $-1.60 | $-1.94 | $-2.36 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $1.19B | $748.96M | $587.81M | $700.12M | $782.62M | $783.18M | $540.20M | $384.51M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $454.96M | $317.20M | $187.40M | $159.23M | $155.61M | $84.05M | $61.12M | $49.22M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $732.79M | $431.75M | $400.41M | $540.89M | $627.01M | $699.13M | $479.08M | $335.29M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $732.79M | $431.75M | $400.41M | $540.89M | $627.01M | $699.13M | $479.08M | $335.29M |
| Total Liabilities & Stockholders Equity | $1.19B | $748.96M | $587.81M | $700.12M | $782.62M | $783.18M | $540.20M | $384.51M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $226.45M | $-61.29M | $-215.97M | $-167.87M | $-281.58M | $-235.26M | $-245.19M | $-289.40M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $157.72M | $16.70M | $-114.03M | $-125.66M | $-136.17M | $-151.13M | $-167.47M | $-217.86M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Why Acadia Pharmaceuticals Stock Is Soaring TodayThe Motley Fool Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?The Motley Fool Questex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards WinnersGlobeNewswire Inc. Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsightGlobeNewswire Inc. Neuroregeneration Therapy Market to Surpass USD 64.8 Billion by 2034, Driven by Advancements in Regenerative Medicine and Rising Neurological Disorders | Transparency Market ResearchGlobeNewswire Inc. This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?Zacks Investment Research Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research
Show 12 more stories
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues MissZacks Investment Research Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings EstimatesZacks Investment Research Ligand Pharmaceuticals (LGND) Tops Q1 Earnings EstimatesZacks Investment Research Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?Zacks Investment Research Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?Zacks Investment Research ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)Benzinga Cracking The Code: Understanding Analyst Reviews For ACADIA PharmaceuticalsBenzinga Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?Zacks Investment Research Expert Ratings For ACADIA PharmaceuticalsBenzinga Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & MoreZacks Investment Research Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionBenzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Discover more
You may be interested in